| 1. |
- Burkitt-Gray, Mary, et al.
(författare)
-
Structural investigations into colour-tuneable fluorescent InZnP-based quantum dots from zinc carboxylate and aminophosphine precursors
- 2022
-
Ingår i: Nanoscale. - : Royal Society of Chemistry (RSC). - 2040-3364 .- 2040-3372. ; 15:4, s. 1763-1774
-
Tidskriftsartikel (refereegranskat)abstract
- Fluorescent InP-based quantum dots have emerged as valuable nanomaterials for display technologies, biological imaging, and optoelectronic applications. The inclusion of zinc can enhance both their emissive and structural properties and reduce interfacial defects with ZnS or CdS shells. However, the sub-particle distribution of zinc and the role this element plays often remains unclear, and it has previously proved challenging to synthesise Zn-alloyed InP-based nanoparticles using aminophosphine precursors. In this report, we describe the synthesis of alloyed InZnP using zinc carboxylates, achieving colour-tuneable fluorescence from the unshelled core materials, followed by a one-pot ZnS or CdS deposition using diethyldithiocarbamate precursors. Structural analysis revealed that the “core/shell” particles synthesised here were more accurately described as homogeneous extended alloys with the constituent shell elements diffusing through the entire core, including full-depth inclusion of zinc.
|
|
| 2. |
- Jayakody, R.R.J.C., et al.
(författare)
-
Role of the Built Environment in Rebuilding Displaced and Host Communities.
- 2021
-
Ingår i: Multi-Hazard Early Warning and Disaster Risk Reduction.. - 9783030730031 ; , s. 69-92
-
Bokkapitel (refereegranskat)abstract
- Disaster-induced and conflict-induced forced displacements areamong the biggest humanitarian and development challenges of the countriesaround the world in the 21st century. The increasing rate of the forced displacementputs significant pressure on the built environment which popularly includes thechallenges associated with delivering the essential goods and services, providingadequate and appropriate housing, and sufficient infrastructure to both host and displaced communities. However, apart from this physical aspect, the built environment has a significant role to play in rebuilding communities addressing the sociocultural, livelihood, and economic aspects and social cohesion between displacedand host communities. The understanding of this complex and multifaceted role ofthe built environment is an essential factor in resettlement planning in order to delivera successful relocation program ensuring the long-term satisfaction of the displacedand host communities. With the identification of this research need, the projecttitled REGARD (REbuild-inG AfteR Displacement) which is a EuropeanCommission funded collaborative research project, investigated the role of the builtenvironment in rebuilding communities following the disaster and conflict-inducedmass displacements.The method involved first reviewing the literature related to the field and conceptualising a framework based on literature synthesis. Data collection was initiated through the selection of participants using purposive sampling which include government officials, community representatives, social support networks, agency networks. A total of 37 interviews were carried out by the 3 partner countries; 12 inthe UK, 11 in Sweden, and 14 in Estonia. In the context of Sri Lanka 10 key informantinterviews and focus group discussions with community members were conducted covering both conflict-induced and disaster-induced displacement.Analysis revealed that the built environment has an instrumental role to play inrebuilding displaced and host communities by acting across six perspectives; constructing physical assets, stimulating economic assets, facilitating institutional assets, developing human capital assets, nurturing social assets, and protecting natural assets. This chapter presents the research findings across these six perspectives synthesising the role of the built environment (BE) in rebuilding communities and enhancing social cohesion between host and displaced communities. Finally, the chapter introduces a comprehensive framework of role of the built environment, summarising the research findings which can be used by the future academics, practitioners, and policymakers in the field of displacement resettlement planning.
|
|
| 3. |
- Haigh, Daisy B., et al.
(författare)
-
The METTL3 RNA Methyltransferase Regulates Transcriptional Networks in Prostate Cancer
- 2022
-
Ingår i: Cancers. - : MDPI. - 2072-6694. ; 14:20
-
Tidskriftsartikel (refereegranskat)abstract
- Prostate cancer (PCa) is a leading cause of cancer-related deaths and is driven by aberrant androgen receptor (AR) signalling. For this reason, androgen deprivation therapies (ADTs) that suppress androgen-induced PCa progression either by preventing androgen biosynthesis or via AR signalling inhibition (ARSi) are common treatments. The N6-methyladenosine (m6A) RNA modification is involved in regulating mRNA expression, translation, and alternative splicing, and through these mechanisms has been implicated in cancer development and progression. RNA-m6A is dynamically regulated by the METTL3 RNA methyltransferase complex and the FTO and ALKBH5 demethylases. While there is evidence supporting a role for aberrant METTL3 in many cancer types, including localised PCa, the wider contribution of METTL3, and by inference m6A, in androgen signalling in PCa remains poorly understood. Therefore, the aim of this study was to investigate the expression of METTL3 in PCa patients and study the clinical and functional relevance of METTL3 in PCa. It was found that METTL3 is aberrantly expressed in PCa patient samples and that siRNA-mediated METTL3 knockdown or METTL3-pharmacological inhibition significantly alters the basal and androgen-regulated transcriptome in PCa, which supports targeting m6A as a novel approach to modulate androgen signalling in PCa.
|
|
| 4. |
- Harris, Anna E., et al.
(författare)
-
Exploring anti-androgen therapies in hormone dependent prostate cancer and new therapeutic routes for castration resistant prostate cancer
- 2022
-
Ingår i: Frontiers in Endocrinology. - : Frontiers Media S.A.. - 1664-2392. ; 13
-
Forskningsöversikt (refereegranskat)abstract
- Androgen deprivation therapies (ADTs) are important treatments which inhibit androgen-induced prostate cancer (PCa) progression by either preventing androgen biosynthesis (e.g. abiraterone) or by antagonizing androgen receptor (AR) function (e.g. bicalutamide, enzalutamide, darolutamide). A major limitation of current ADTs is they often remain effective for limited durations after which patients commonly progress to a lethal and incurable form of PCa, called castration-resistant prostate cancer (CRPC) where the AR continues to orchestrate pro-oncogenic signalling. Indeed, the increasing numbers of ADT-related treatment-emergent neuroendocrine-like prostate cancers (NePC), which lack AR and are thus insensitive to ADT, represents a major therapeutic challenge. There is therefore an urgent need to better understand the mechanisms of AR action in hormone dependent disease and the progression to CRPC, to enable the development of new approaches to prevent, reverse or delay ADT-resistance. Interestingly the AR regulates distinct transcriptional networks in hormone dependent and CRPC, and this appears to be related to the aberrant function of key AR-epigenetic coregulator enzymes including the lysine demethylase 1 (LSD1/KDM1A). In this review we summarize the current best status of anti-androgen clinical trials, the potential for novel combination therapies and we explore recent advances in the development of novel epigenetic targeted therapies that may be relevant to prevent or reverse disease progression in patients with advanced CRPC.
|
|
| 5. |
- Metzler, Veronika M., et al.
(författare)
-
The KDM5B and KDM1A lysine demethylases cooperate in regulating androgen receptor expression and signalling in prostate cancer
- 2023
-
Ingår i: Frontiers in Cell and Developmental Biology. - : Frontiers Media S.A.. - 2296-634X. ; 11
-
Tidskriftsartikel (refereegranskat)abstract
- Histone H3 lysine 4 (H3K4) methylation is key epigenetic mark associated with active transcription and is a substrate for the KDM1A/LSD1 and KDM5B/JARID1B lysine demethylases. Increased expression of KDM1A and KDM5B is implicated in many cancer types, including prostate cancer (PCa). Both KDM1A and KDM5B interact with AR and promote androgen regulated gene expression. For this reason, there is great interested in the development of new therapies targeting KDM1A and KDM5B, particularly in the context of castrate resistant PCa (CRPC), where conventional androgen deprivation therapies and androgen receptor signalling inhibitors are no longer effective. As there is no curative therapy for CRPC, new approaches are urgently required to suppress androgen signalling that prevent, delay or reverse progression to the castrate resistant state. While the contribution of KDM1A to PCa is well established, the exact contribution of KDM5B to PCa is less well understood. However, there is evidence that KDM5B is implicated in numerous pro-oncogenic mechanisms in many different types of cancer, including the hypoxic response, immune evasion and PI3/AKT signalling. Here we elucidate the individual and cooperative functions of KDM1A and KDM5B in PCa. We show that KDM5B mRNA and protein expression is elevated in localised and advanced PCa. We show that the KDM5 inhibitor, CPI-455, impairs androgen regulated transcription and alternative splicing. Consistent with the established role of KDM1A and KDM5B as AR coregulators, we found that individual pharmacologic inhibition of KDM1A and KDM5 by namoline and CPI-455 respectively, impairs androgen regulated transcription. Notably, combined inhibition of KDM1A and KDM5 downregulates AR expression in CRPC cells. Furthermore, combined KDM1A and KDM5 inhibition impairs PCa cell proliferation and invasion more than individual inhibition of KDM1A and KDM5B. Collectively our study has identified individual and cooperative mechanisms involving KDM1A and KDM5 in androgen signalling in PCa. Our findings support the further development of KDM1A and KDM5B inhibitors to treat advanced PCa. Further work is now required to confirm the therapeutic feasibility of combined inhibition of KDM1A and KDM5B as a novel therapeutic strategy for targeting AR positive CRPC.
|
|
